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Purpose: To study the risk of recurrence in acute central serous chorioretinopathy (aCSC)
and to evaluate the risk of transitioning to chronic CSC.
Patients and Methods: The medical records and multimodal imaging data of 295 aCSC cases
were reviewed. Typical aCSC was defined as the presence of serous subretinal fluid (SRF), one
focal leakage spot on fluorescein angiography (FA), retinal pigment epithelium (RPE) alterations
limited in area to less than one optic disc diameter, and complete recovery from this first CSC
episode. An increase in RPE alterations combined with persistent SRF was considered a sign of
chronicity, which was determined in cases with >12 months follow-up. The main outcome
measures included final visual acuity, percentage of disease recurrence, and percentage of cases
moving toward a chronic phenotype. Treatment strategies and their efficacy were also reviewed.
Results: A total of 295 eyes in 291 patients with aCSC were included. Spontaneous recovery
was awaited in 154 eyes (52%), whereas 141 eyes (48%) recovered following treatment. SRF
recurrence occurred in 24% of untreated cases and in 4% of treated cases (p<0.001). An analysis
of 61 eyes that underwent an FA after ≥12 months of follow-up revealed increased RPE
alterations in 22 eyes (36%), and 14 eyes (23%) had both an increase in RPE alterations and
SRF recurrence.
Conclusion: All aCSC cases recovered from the first disease episode, and none of the cases
developed persistent SRF leakage. Among the cases for which long-term follow-up informa-
tion was available, 36% showed a tendency toward chronicity in terms of increased RPE
alterations, whereas 23% showed both an increase in RPE alterations and recurrent SRF.
Early photodynamic therapy (PDT) may decrease the risk of recurrences.
Keywords: acute central serous chorioretinopathy, chronic CSC, photodynamic treatment,
recurrent CSC
Introduction
Central serous chorioretinopathy (CSC) is characterized by an accumulation of serous
fluid under the retina.1 This subretinal fluid (SRF) is believed to accumulate as the result
of a dysfunctional, hyperpermeable choroid together with a disruption in the retinal
pigment epithelium (RPE), which compromises the outer blood-retinal barrier.2
Generally, CSC can present as either an acute or chronic form. Acute CSC (aCSC)
is usually self-limiting, with a good visual prognosis.2 In contrast, in chronic CSC, the
SFR usually does not resolve spontaneously, and may result in irreversible photore-
ceptor damage, vision loss and a decreased vison-related quality of life.3–5 Therefore,
treatment is generally recommended for chronic CSC.
It is unclear whether aCSC and cCSC are different entities or if they are part of
a spectrum of diseases and whether aCSC can transition to cCSC, and if so, what
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factors may contribute to this process. Also, there is no
consensus regarding the exact period after which CSC
should be considered chronic; some authors suggest that
typical aCSC resolves spontaneously within 2–4 months,6
whereas others suggest a duration of 6 months.7,8 It is also
unclear whether chronic CSC is usually preceded by
aCSC.
There are clinical features in addition to disease duration
that can help distinguish between acute CSC and chronic
CSC. Chronic CSC tends to manifest with more widespread
abnormalities on multimodal imaging compared to aCSC.9
In cCSC, optical coherence tomography (OCT) shows dis-
ruption of the outer retinal layers, RPE irregularities and/or
detachment, and posterior cystoid retinal degeneration.10,11
Fluorescein angiography (FA) shows gravitational tracks,
multiple “pin points” or diffuse RPE leakage, and/or wide-
spread areas of atrophic RPE alterations. Indocyanine green
angiography (ICGA) shows signs of multifocal hyper-
permeable choroidal congestion and hyperpermeability.4
Fundus autofluorescence (FAF) imaging shows extensive
hyper-autofluorescent and hypo-autofluorescent changes.12
Unlike chronic CSC, an episode of aCSC is generally
defined as only a single leak on FA with minimal focal
changes in the RPE.13–15
Little is known about which aCSC patients are at risk
for developing recurrent and/or chronic CSC. Therefore,
better insight into the clinical course, risk factors, and
long-term outcome of aCSC can be helpful in determining
whether these diseases largely overlap or are pathophysio-
logically and clinically distinct. Here, we reviewed a large
number of patients who presented with their first episode
of typical aCSC based on multimodal imaging character-
istics. These patients were followed over time in order to
evaluate the prevalence of recurrence and to identify the
clinical features that can be used to predict the transition of
aCSC to chronic CSC.
Patients and Methods
Patient Selection
This study was approved by the respective institutional
review boards at the participating centers and was per-
formed in accordance with the tenets of the Declaration
of Helsinki. No written consent had to be collected for
reviewing the medical records, as all data were anon-
ymized upon collection. In this retrospective multicenter
study, subjects were identified from a large cohort of CSC
patients seen from January 2005 until December 2017 at
two Dutch tertiary referral centers: The Department of
Ophthalmology at Leiden University Medical Center
(Leiden, the Netherlands) and the Rotterdam Eye
Hospital (Rotterdam, the Netherlands). Patients who met
the clinical definition of aCSC, had at least one follow-up
visit, and had evidence of complete resolution of the first
CSC episode were included. Acute CSC was defined as: 1.
documented presence of SRF on OCT; 2. only one focal
leakage (“hot spot”) on FA; 3. limited RPE alterations,
including RPE detachment, less than one optic disc dia-
meter. Patients were excluded when there was a suspicion
of other possible causes of SRF accumulation, such as
choroidal neovascularization, or polypoidal choroidal vas-
culopathy. In this study, previous steroid use was not an
exclusion criterion.
Clinical Examinations
Patients underwent a range of ophthalmological and multi-
modal imaging examinations both at the time of diagnosis
and during follow-up visits. These examinations included
best-corrected visual acuity (BCVA, measured with
a Snellen chart, then converted to ETDRS letters for statis-
tical comparison);16 slit-lamp examination and/or color fun-
dus photography (Topcon Corp., Tokyo, Japan or Carl Zeiss
Meditec AG, Jena, Germany); spectral-domain OCT (Cirrus
HD-OCT, Carl Zeiss Meditec, Jena, Germany, OCT-HS100,
Canon Inc., Tokyo, Japan, or Spectralis HRA+OCT,
Heidelberg Engineering, Heidelberg, Germany); fundus
autofluorescence imaging (FAF) (Heidelberg Spectralis
HRA+OCT or Topcon Corp.); FA (Topcon Corp.,
Spectralis HRA+OCT, or Carl Zeiss Meditec); and ICGA
(Topcon Corp., Heidelberg Spectralis HRA+OCT, or Carl
Zeiss Meditec).
Clinical Outcome Measures
For this study, patients were subdivided into the following
two groups based on available follow-up data: patients
with ≥12 months follow-up, and patients with <12 months
of follow-up. Only patients with ≥12 months of follow-up
data were included in our analysis of disease progression
over time. Follow-up began at the first episode of CSC
confirmed by an ophthalmologist and ended with the last
available visit. The following clinical characteristics were
obtained: presence and location of SRF on OCT; abnorm-
alities on FAF; RPE alterations on FA; SRF leakage on
FA; and the aspect of the hyperpermeable choroid areas on
ICGA. In addition, the presence of RPE alterations in the
unaffected contralateral eye was assessed. RPE alterations
Mohabati et al Dovepress
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were defined as patches of granular hyperfluorescence as
seen on mid-phase FA. The amount of RPE alterations,
and the extension of the area of RPE alterations, were
evaluated by two experienced retina specialists (SY and
CJFB). All clinical management strategies were also
reviewed and included photodynamic therapy (PDT), con-
ventional thermal laser, subthreshold micropulse diode
laser (SML), and a “wait-and-see” policy. CSC was con-
sidered to be recurrent when SRF returned at least once
following complete resolution. Signs of chronic CSC were
defined as the persistence and/or recurrence of SRF
together with an increased area of cumulative RPE altera-
tions based on follow-up FA imaging. Patients with aCSC
who were followed for less than 12 months were contacted
by telephone and questioned regarding any complaints
suggestive of recurrent CSC (either with or without con-
sulting an ophthalmologist) since their final follow-up
visit.
Statistical Analysis
Statistical analyses were performed using IBM SPSS
software for Windows, version 23 (IBM Corp., Armonk,
NY, USA). Continuous numerical data were compared
using either a paired or an unpaired samples Student’s
t-test. Categorical data were analyzed using a chi-square
test. A univariate analysis was performed using Pearson’s
correlation in order to evaluate the correlation between




The clinical records of 1378 patients with a diagnosis of
CSC were reviewed. A total of 295 eyes in 291 patients
met our strict definition of aCSC and were included in our
analysis. For 201 eyes (68%), ≥12 months of follow-up
data were available (mean: 37 months; range: 12–247
months); the mean follow-up time for the remaining 94
eyes was 5 months (range: 1–11 months). The demo-
graphic characteristics of these cases are summarized in
Table 1. Four of the included patients had a history of
bilateral aCSC with an average interval of 28 months
(range: 6–63 months) between disease onset in the first
affected eye and the second affected eye. Of the 73 female
patients, five had a unilateral case of aCSC during preg-
nancy, and all five cases recovered spontaneously after
delivery.
Optical Coherence Tomography
OCT imaging was available for all 295 eyes at diagnosis
and for 292 eyes (99%) at the final follow-up visit. SRF on
OCT at disease onset was subfoveal in 286 eyes (97%) and
extrafoveal in 7 eyes (2%); in the remaining 2 eyes (1%),
SRF resolved in the period between the fundus examina-
tion and the first imaging examination. Unresolved SRF
was present at the final available OCT examination in 7
out of 292 eyes (2%) (Table 2).
Fundus Autofluorescence Imaging
FAF imaging was available for 199 eyes (67%) at the time of
diagnosis and for 77 eyes (26%) at the final follow-up visit. At
diagnosis, CSC-associated FAF changes at the site of serous
neuroretinal detachment could be categorized as: focal hyper-
autofluorescent lesion (21 eyes, 10%), hypo-autofluorescent
lesions (54 eyes, 27%), a combination of both lesions (33 eyes,
17%), and speckled (ie, granular) hyper-autofluorescent lesion
with mottled hyper-autofluorescent dots (63 eyes, 32%)
(Table 2, and Figure 1).
Fluorescein Angiography
FA imaging was available at the time of diagnosis for 232
eyes (79%). Long-term follow-up FA data were available
for 61 eyes (21%) with a mean interval of 37±33 months
between the initial diagnosis and the final follow-up visit.
At diagnosis, no RPE alterations were present in 91 eyes
(39%), whereas minimal RPE alterations were observed in
the remaining 141 eyes (61%). These RPE changes were
located in the fovea in 24 of these 141 eyes (10%), 1 disc
diameter (DD) round but excluding the fovea in 41 eyes
(18%), and 1 DD away from the fovea in 60 eyes (26%).
Minimal RPE alterations and RPE detachment were pre-
sent in more than one area in 16 eyes (7%) (Table 2).
Table 1 Patient Demographics and Clinical Features
Feature Value
Patients (eyes) 291 (295)
Age at diagnosis in years, mean ± SD 44±9
Male gender, N (%) 220 (75%)
Caucasian, N (%) 244 (83%)
Recent steroid use, N (%) 59 (20%)
Pregnancy-associated CSC, N (%) 5 (1.7%)
BCVA at diagnosis, in ETDRS letters, mean ± SD
(Snellen equivalent)
79±9 (~20/25)
Mean follow-up duration (range) 27 months (1–247)
Abbreviations: BCVA, best corrected visual acuity; CSC, central serous chorior-
etinopathy; ETDRS, Early Treatment Diabetic Retinopathy Study.
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Cases with <12 Months
Follow-Up (n=94 Eyes)





OCT Eyes with available OCT 295 eyes 94 eyes 198 eyes 292 eyes
Location SRF (%) No SRF 2 (1) 89 (95) 196 (99) 285 (97)
Central 286 (97) 3 (3) 2 (1) 5 (2)
Peripheral 7 (2) 2 (2) 0 2 (1)
FAF Eyes with available FAF 199 eyes 10 eyes 67 eyes 77 eyes








54 (27) 1 (10) 25 (37) 26 (34)




63 (32) 0 0 0
FA Eyes with available FA 232 eyes 3 eyes 61 eyes 64 eyes
Location RPE alterations (%) No RPE
alterations
91 (39) 0 10 (16) 10 (15)
Foveal 24 (10) 1 (33) 6 (10) 7 (11)
<1 DD from fovea 41 (18) 1 (33) 13 (21) 14 (22)
>1 DD from fovea 60 (26) 1 (33) 27 (44) 28 (44)
Multiple locations 16 (7) 0 5 (9) 5 (8)
Composition RPE alterations (%) Monofocal 75 (53) 2 (66) 28 (55) 30 (56)
Multifocal 66 (47) 1 (33) 23 (45) 24 (44)




135 (58) 0 33 (54) 33 (52)
Minimal RPE
alterations
90 (39) 0 23 (38) 23 (36)
Bilateral CSC 6 (2) 3 (100) 5 (8) 8 (12)
Missing image 1 (1) 0 0 0
Location of “hot spot” of leakage
on FA (%)
Foveal 39 (17) 1 (33) 4 (7) 5 (8)
<1 DD from fovea 89 (38) 1 (33) 14 (24) 15 (24)
>1 DD from fovea 104 (45) 1 (33) 9 (15) 10 (16)
Hot spot morphology (%) Smoke stack 47 (20) 0 2 (4) 2 (3)
Ink blot 185 (80) 3 (100) 25 (42) 28 (45)
ICGA Eyes with available ICGA 54 eyes 4 eyes 19 eyes 23 eyes
Composition hyperpermeable area
(%)
Monofocal 34 (63) 1 (25) 11 (58) 12 (52)
Multifocal 20 (37) 3 (75) 8 (42) 11 (48)
Hyperpermeable area compared
to RPE alterations area on FA (%)
Equal to FA 24 (44) 0 11 (58) 11 (48)
Smaller than FA 0 0 0 0
Larger than FA 30 (56) 4 (100) 8 (42) 12 (52)
Abbreviations: CSC, central serous chorioretinopathy; DD, optical disc diameter; FA, fluorescein angiography; FAF, fundus autofluorescence; ICGA, indocyanine green
angiography; OCT, optical coherence tomography; RPE, retinal pigment epithelium; SRF, subretinal fluid.
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Indocyanine Green Angiography
ICGA imaging was available for 54 eyes (18%) at diag-
nosis and 23 eyes (8%) at the final visit, which was on
average 11±15 months after the first ICGA. On mid-phase
ICGA (ie, 10 minutes), a monofocal hyperfluorescent and
hyperpermeable region in the choroid was visible in 34
eyes (63%). Multifocal hyperfluorescent lesions were seen
in 20 eyes (37%), even though all of the patients included
in this study had only one leakage spot on FA imaging
(Table 2, Figure 2). At the time of diagnosis, 30 eyes
(56%) had a hyperfluorescent ICGA lesion that exceeded
the size of the RPE alteration shown on FA imaging; in the
remaining 24 eyes (44%), the extent of the hyperfluores-
cent choroidal abnormalities was equal to the extent of the
RPE alterations on FA (Table 2, Figure 2).
Treatment, Resolution of SRF, and Visual
Outcome
In total, 154 eyes (52%) had spontaneous resolution of the
first aCSC episode (the wait-and-see group) 14.8±11.6
weeks after diagnosis; the remaining 141 eyes (48%)
received treatment (applied on average 13.7±12.7 weeks
Figure 1 Clinical features visible on multimodal imaging of the left eye of a 37-year-old male patient with aCSC. (A) Color fundus photograph showing small pigment
clustering in the macula and a silhouette of the serous retinal detachment. The arrow indicates the scanning plane, which is depicted on the SD-OCT. (B) FAF image at
diagnosis showing a speckled (ie, granular) hyper-autofluorescent lesion at the site of the serous neuroretinal detachment. (C) FA imaging revealed a single “hot spot” of
leakage and a typical small detachment of the RPE above the inferior retinal arcade (arrow). (D) An SD-OCT scan at diagnosis revealed SRF accumulation, a thickened
choroid, and subretinal debris, presumably consisting of non-phagocytized photoreceptor outer segments. (E) SRF resolved spontaneously within a few weeks. (F) The areas
of hyper-fluorescence on mid-phase ICGA revealed diffuse choroidal hyperpermeability that was larger than the leakage site visible on FA. A recurrent episode 1.5 years later
was treated with two subthreshold micropulse diode laser but did not result in resolution of the SRF. Eventually, half-dose photodynamic therapy resulted in resolution of the
SRF (G and H). At the patient’s final visit 11 months later, hyper-autofluorescent and hypo-autofluorescent abnormalities were visible (G), and FA imaging revealed a slightly
enlarged area of RPE alterations (H).
Abbreviations: aCSC, acute central serous chorioretinopathy; ICGA, indocyanine green angiography; FA, Fluorescein angiography; FAF, Fundus autofluorescence; SD-OCT,
spectral-domain optical coherence tomography; SRF, subretinal serous fluid; RPE, retinal pigment epithelium.
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Figure 2 Clinical features visible on multimodal imaging of the right eye of a 37-year-old female patient (A–D) and a 34-year-old male patient (E–H) with aCSC. (A and E) FA
revealed one focal “hot spot” of leakage and no changes in the retinal pigment epithelium. (B and F) Despite these circumscribed lesions on FA, ICGA revealed a more widespread
area of hyper-fluorescence, which corresponded with multifocal (B) or monofocal (F) choroidal leakage. (C and G) FAF imaging revealed speckled (ie, granular) hyper-
autofluorescent changes at the site of serous neuroretinal detachment in both patients, which corresponded with serous retinal detachment visualized on OCT (D, H).
Abbreviations: aCSC, acute central serous chorioretinopathy; ICGA, indocyanine green angiography; FA, Fluorescein angiography; FAF, Fundus autofluorescence; OCT,
optical coherence tomography; SRF, subretinal serous fluid; RPE, retinal pigment epithelium.
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after diagnosis) and all resolved, on average in 9.6±10.2
weeks after this treatment. SRF resolution occurred sig-
nificantly faster after treatment compared to resolution
after a wait-and-see strategy (p<0.001). The choice of
treatment modalities, which was at the discretion of the
treating physician, is summarized in Table 3.
The average subjective reported interval between the
onset of complaints and aCSC diagnosis was 4 weeks
(range: 0–52 weeks; median: 1 week) in the early-treated
patients, and 6 weeks (range: 0–52 weeks; median: 1 week)
in the wait-and-see group; this difference was not significant
(p=0.136). Moreover, these two groups did not differ signifi-
cantly with respect to the location of the leakage “hot spot”
(p=0.540), the presence of RPE alterations (p=0.821), or the
extent of the RPE alterations (p=0.439).
Mean BCVA in the entire patient cohort was 79±9
ETDRS letters (Snellen equivalent: ~20/25) at the time of
diagnosis and increased significantly to 86±6 ETDRS
(Snellen equivalent: ~20/20) letters at the final follow-up
visit (p<0.001). Initial BCVA in the early-treated group was
significantly lower than in the wait-and-see group (78±9
ETDRS letters (Snellen equivalent: ~20/32) versus 80±9
ETDRS letters (Snellen equivalent: ~20/25), respectively;
p=0.017), but did not differ significantly between groups at
the final follow-up visit (86±5 ETDRS letters (Snellen
equivalent: ~20/20) versus 86±7 ETDRS letters respectively;
p=0.971). In total, final BCVA was ≥80 ETDRS letters
(Snellen equivalent: ~20/25) in 94% of eyes, and ≥85
ETDRS letters (Snellen equivalent: ~20/20) in 76%.
Self-Reported Complaints
Among patients with <12 months clinical follow-up (94
aCSC eyes), 3 patients (3 eyes, 3%) reported additional
aCSC episodes through telephone survey. None of these
patients had consulted an ophthalmologist since all
reported episodes had resolved spontaneously. One patient
reported 5 aCSC episodes during 2 years, each lasting less
than 1 week. The second patient reported 2 episodes in 2
years, lasting for less than 2 weeks each. The third case
reported 2 episodes during 3 years each lasting for less
than 1 week (Figure 3).
Transition to Recurrent and/or Chronic
CSC
Among the 201 eyes with ≥12 months of documented
follow-up data, 75 (37%) had an average of 1.4 recurrences
(range: 1–6 recurrences) with a mean follow-up of 53
months (range: 13–247 months). Among the 94 eyes with
<12 months of follow-up data, 9 eyes (10%) had an average
of 1.3 recurrences (range: 1–2 recurrences) documented by
an ophthalmologist; 3 additional eyes had documented self-
reported recurrences through the telephone survey. Thus,
from the original cohort of 295 eyes with aCSC, a total of 87
eyes (29%) had evidence of recurrent CSC. The prevalence
of SRF recurrence was significantly higher in the wait-and-
see group compared to the early-treated group (24% versus
4%, respectively; p<0.001). Moreover, Pearson’s correla-
tion analysis revealed a significant correlation between
treatment and reduced risk of recurrence (R=−0.333;
p<0.001). No other significant correlation was found
between any demographic or clinical characteristics and
the risk of recurrence, with the sole exception of the
patient’s age at diagnosis (R=−0.161; p=0.005), which
was on average 4 years lower in the patients with
a recurrence compared to the patients without a recurrence
Table 3 Treatment Modalities and Specifications During Follow-










Eyes not treated at first episode
[wait-and-see approach] (%)
154 (52) 47 (50) 107 (51)
Eyes treated at first episode
[early-treatment group] (%)




PDTa 134 (95) 43 (92) 91 (97)
Conventional
laser
3 (2) 2 (4) 1 (1)
SML 4 (3) 2 (4) 2 (2)
Eyes with additional treatments
after first episode (%)
23 (8) 1 (1) 22 (11)
Average number of retreatments
(range)




PDTb 71 (93) 1 (50) 70 (94)
Conventional
laser
2 (3) 0 2 (3)
SML 3 (4) 1 (50) 2 (3)
Notes: a56 (42%) eyes received half-dose PDT, 67 (50%) eyes received half-time
PDT, and 11 eyes (8%) had unknown PDT settings; mean spot size: 1746±1109 µm.
b28 (39%) eyes received half-dose PDT, 40 (57%) eyes received half-time PDT, and 3
(4%) eyes had full PDT settings; mean spot size: 2066±1256 µm.
Abbreviations: CSC, central serous chorioretinopathy; PDT, photodynamic ther-
apy; SML, subthreshold micropulse diode laser.
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(41 years versus 45 years, respectively; p=0.005). The dis-
tribution of eyes with recurrent disease and additional treat-
ment are summarized in Figure 3.
With respect to the progression of RPE alterations
in the 61 eyes (21%) with long-term follow-up FA
examination, a clear increase in lesion size was
observed in 22 of these eyes (36%). In 14 of these
eyes (23%) both an increase in RPE alterations and
recurrent SRF was observed. Furthermore, 23 unaf-
fected contralateral eyes (37%) had minimal RPE
alterations —but no active disease—at the final follow-
up visit. A significant correlation was found between
the progression of RPE alterations in the affected eyes
and the presence of RPE alterations in the unaffected
contralateral eyes at the final follow-up visit (R=0.346;
p=0.008). Among the 201 eyes with ≥12 months of
follow-up data, 10 eyes (10/107, 9%) in the wait-and-
see group and 4 eyes (4/94, 4%) in the early-treated
group had both SRF recurrence and an increased area
of RPE alterations (Figure 3). However, a Pearson’s
correlation analysis showed no correlation between
the progression of RPE alterations on one side, and
the wait-and-see or treatment strategy on the other
side (R=−0.103; p=0.448). Finally, disease recurrence
(presence of SRF) was not significantly correlated with
the progression of RPE alterations (R=0.258; p=0.162).
Figure 3 Flow chart depicting the distribution of the eyes in this study, with follow-up durations indicated. The development of CSC over time is based on recurrence of the
disease, progression of RPE alterations, and the need for additional treatments.
Abbreviations: CSC, cute central serous chorioretinopathy; RPE, retinal pigment epithelium.
Mohabati et al Dovepress
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Discussion
Little is currently known regarding the risk of acute CSC
transitioning to a chronic form of CSC. Previous reports
indicated that 8–16% of patients with chronic CSC have
a history of aCSC.6,17 In our retrospective study, 36% of
eyes with long-term follow-up data began as typical aCSC
and showed a clear progression of RPE alterations over
time; therefore, these patients showed a tendency toward
chronic disease. Wong et al previously reported a higher
percentage of progressive RPE alterations (61%) in
a smaller cohort of 25 patients with aCSC who were
followed for at least 5 years after initial resolution; how-
ever, they found no correlation between this progression
and visual acuity.18
In addition to changes in the RPE, persistent SRF is
a characteristic feature of chronic CSC.19 In our study,
none of the patients with long-term follow-up data had
chronic persistent SRF. However, 23% of these patients
had a combination of recurrent SRF and progressive RPE
alterations, which could be considered chronic CSC in the
strictest sense, as the presence of increased RPE changes
alone may not necessarily be considered evidence of
chronic disease. Nevertheless, an increase in RPE changes
in the absence of active SRF leakage may still be a sign of
chronic dysfunction of the underlying choroid. CSC is
considered part of the pachychoroid disease spectrum,
which is characterized by a congested and hyperpermeable
choroid.20 In CSC, a thickened, leaking choroid may exert
pressure on the overlying RPE, gradually causing struc-
tural changes that can lead to the focal breakdown of the
outer blood-retina barrier formed by the RPE, with subse-
quent serous neuroretinal detachment.21 Bilateral RPE
changes are often present in patients with pachychoroid
pigment epitheliopathy.21–23 In our cohort, 61% of affected
eyes and 42% of unaffected contralateral eyes had minimal
(ie, <1 DD) RPE changes at the time of diagnosis, con-
sistent with pachychoroid pigment epitheliopathy. In this
condition, chronic changes in the choroid are common and
are often independent of active leakage. Therefore, an
objective increase in RPE alterations may actually be
a more robust indicator of chronic disease than the dura-
tion of persisting SRF, as is currently customary in clinical
practice.24
In our study, 29% of all cases had a recurrence of SRF.
This percentage includes patients with limited documented
follow-up data and patients who self-reported an episode
by telephone survey. However, when considering only the
patients with objective long-term follow-up data, the pre-
valence of recurrent SRF leakage was higher (37%).
Therefore, our data suggest that the true rate of recurrence
in typical aCSC lies somewhere between 29% and 37%,
which is consistent with the sole study published regarding
this topic.25 In our analysis, although the patients with
recurrent disease were significantly younger than the non-
recurrent patients, no other demographic or clinical char-
acteristics were associated with the recurrence of SRF.
Disease recurrence was also not correlated with progres-
sive changes in the RPE, which are often considered an
important sign of a more chronic form of CSC. This might
suggest that underlying choroidal changes—without active
SRF leakage—are sufficient to cause changes in the RPE.
Therefore, to a certain extent chronic CSC and recurrent
CSC might represent two distinct disease entities.
However, even in these cases we cannot exclude the pos-
sibility of intermittent mild SRF leakage as the cause of
progressive RPE changes.
There is currently no universally accepted classification
of clinical CSC subtypes, and the description and termi-
nology of CSC and its subtypes is therefore a topic of
debate. For example, some groups have proposed the
following five categories for classifying the various phe-
notypes: acute CSC, non-resolving CSC, recurrent CSC,
chronic CSC, and inactive CSC.14,26 Matet et al recently
reported a strong correlation between increased choroidal
thickness and the risk of recurrence in CSC.25 A similar
mechanism of action might have been present in our
cohort. Although our data set lacked sufficient numbers
of choroidal thickness measurements to assess this puta-
tive correlation, we frequently observed a thickened chor-
oid (Figure 1). In our study cohort, SRF resolved faster in
the treatment group compared to the wait-and-see group,
and the prevalence of SRF recurrence was significantly
lower in the group that received treatment (4% versus 24%
respectively), the majority of whom received PDT with
reduced settings. Similarly, Ozkaya et al reported a two-
fold higher rate of recurrence in 41 untreated self-limiting
aCSC cases compared to 36 aCSC patients who were
treated with low-fluence PDT (51% vs 25%,
respectively).27 Given that PDT treatment exerts its effects
at the level of the choroid, it is conceivable that PDT not
only accelerates the resorption of SRF by alteration of
choroidal circulation,28 but it may also play a role in
remodeling the choriocapillaris and Haller’s layer vessels,
thereby reducing choroidal thickness and the risk of dis-
ease recurrence.29
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This study has some limitations that warrant discus-
sion. First, due to the cross-sectional design, the patient
data and imaging examinations were not available at simi-
lar follow-up intervals. We therefore only studied
a subgroup of patients with relatively long-term follow-
up FA data. Second, given that follow-up FA examinations
are usually performed in cases of recurrent SRF and/or the
suspicion of other retinal abnormalities, this subgroup may
have been subject to selection bias. A third possible lim-
itation is that the patients who had early complete recovery
were often referred back to the referring ophthalmologist,
and were therefore lost to follow-up. We attempted to
address this issue by conducting telephone surveys of
these patients; however, 36% of these patients could not
be reached. Finally, some patients in the early-treatment
group were treated relatively soon after diagnosis. This
treatment may have been due to relatively worse
visual acuity and/or a longer history of subjective com-
plaints; however, subjective complaints duration did not
differ significantly between the wait-and-see group and
the early-treated group. Therefore, we cannot exclude the
possibility that at least some of the patients in the early-
treatment group would have resolved spontaneously with-
out treatment.
Conclusion
We report that approximately one-third of aCSC cases devel-
oped a recurrent episode of SRF leakage. An increase of
atrophic RPE alterations was seen in 36% of the cases with
long-term follow-up, and an increase of RPE alterations
together with recurrent SRF in 23% of the cases; however,
none of the patients in our study developed long-term
chronic, persistent SRF leakage. Moreover, the presence of
RPE alterations in the unaffected contralateral eye was asso-
ciated with an increase in RPE alterations in the affected
eye, possibly reflecting chronic disease. Treatment with low-
setting PDT may be an effective means to significantly
reduce the risk of recurrence, but prospective randomized
controlled studies are needed to address this topic. Finally,
our data suggest that there may be a certain degree of clinical
overlap between aCSC and chronic CSC, as a subgroup of
aCSC cases had both recurrent SRF and increased RPE
alterations that may be viewed as signs of a transition to
a more chronic form of the disease. In the future, long-term
prospective studies will likely provide important insights
into possible new biomarkers for predicting the transition
to chronic CSC, and genetic studies may shed light on
possible genetic risk factors.
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